Douglas Mann, MD
Cardiovascular Disease · Saint Louis, MONPI 1801807763
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $42,099 of the $50,034 with a category attached, or 84.1%. 10 manufacturers reported payments, led by Novo Nordisk AS at 33.2% of the total. Reporting peaked in 2022 at $20,152 and has fallen 83.2% since, to $3,386 in 2024. Among cardiovascular disease clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 27 payments — averaging $1853.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$17K
- Novo Nordisk$13K
- E.r. Squibb & Sons, L.L.C.$9K
- Abiomed$6K
- AstraZeneca$3K
- Livanova USA, Inc.$2K
- plus $2K from 4 others
Across 1 payment — averaging $1746.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis Pharma AG$2K
What the payments were for
- Consulting fees$42,09984%
- Travel & lodging$7,44715%
- Food & beverage$4171%
- Education$700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 7 | $16,588 |
| Novo Nordisk | 5 | $12,739 |
| E.r. Squibb & Sons, L.L.C. | 3 | $8,842 |
| Abiomed | 3 | $5,591 |
| AstraZeneca | 2 | $3,222 |
| Livanova USA, Inc. | 3 | $1,500 |
| Sarepta Therapeutics, Inc. | 1 | $1,260 |
| Abbott | 1 | $164 |
| Amicus Therapeutics, Inc. | 1 | $70 |
| Novartis Pharma AG | 1 | $58 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Victoza$12,739
- Impella$5,571
- CAMZYOS$1,950
- VNS - Vitaria$1,500
- CARDIOMEMS$164
How this compares
$50,034 in reported general payments places this provider in the 90th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 12 | $13,912 |
| EliquisApixaban | 15 | $6,035 |
| Kapspargo SprinkleMetoprolol Succinate | 12 | $761 |
| Atorvastatin Calcium | 29 | $446 |
| Eplerenone | 11 | $272 |
| Metoprolol Succinate | 17 | $184 |
| Spironolactone | 14 | $89 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Saint Louis
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- Osler Jay GuzonSaint Louis$211K
- Mohammad TahirSaint Louis$173K
- Robert RifkinSaint Louis$145K
- Martin SchwarzeSaint Louis$113K
- Joshua MitchellSaint Louis$103K
- Zainab MahmoudSaint Louis$100K
- Nizar AssiSaint Louis$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.